Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Angiogenesis Inhibitors - State-of-the-Science and Strategic Opportunities' returned 73 results - Page 1 of 4   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report   Global Industry Analysts, Inc., Feb 2011, Pages: 682 and custom watermarks. For information on site licence pricing please click on Enquire before buying ANGIOGENESIS INHIBITORS AND STIMULATORS A GLOBAL STRATEGIC BUSINESS REPORT CONTENTS 1 Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others   Bioseeker, Jan 2012, Pages: 1704 This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline   Bioseeker, Sep 2010, Pages: 1227 This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4763 This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Protein Kinase Inhibitors. Each of these three individual parts Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides   Bioseeker, Jan 2012, Pages: 4052 This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Peptides Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4059 This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4202 This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4293 This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4469 This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 4100 This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 3923 This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 3756 This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 3984 This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Each of these three Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors   Bioseeker, Jan 2012, Pages: 3805 This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors. Each of these three individual parts Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies   Bioseeker, Jan 2012, Pages: 5090 This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies Challenges and Opportunities in Developing Chemopreventive Agents   Decision Resources, Inc., Nov 2007, Pages: 29 Agents EGFR Inhibitors HMG-CoA Reductase Inhibitors Angiogenesis Inhibitors Matrix Metalloproteinases Combination Therapies Strategic Alliances with Nutraceutical Companies Biomarker Development Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth   Datamonitor, April 2010, Pages: 243 with greater efficacy Small molecules Small molecules targeting tyrosine kinases have been a significant development in oncology drug discovery Classification of pipeline products Angiogenesis inhibitor Histone Deacetylase inhibitors   Lead Discovery, May 2005 inhibitors has been driven by their ability to modulate transcriptional activity. As a result, this therapeutic class is able to block angiogenesis and cell cycling, and promote apoptosis and differentiation U.S. Emerging Cancer Therapeutics Markets   Frost & Sullivan, Jan 1999 .S. Market for Angiogenesis Inhibitors - Strategic Analysis and Forecasts of the Total Market - Competitive Structure - Research and Development Pipeline - The Role of Market Engineering in the Pharmaceutical The Complete Guide to Targeted Therapies in Oncology: A World Review   Bioseeker, Dec 2006, Pages: 550 .2.3 Integrins in Angiogenesis 10.2.4 Inhibitors of Angiogenesis 10.3 Vascular Targeting Agents 10.4 Vascular Disruptive Agents 10.5 Competitive Landscape in Anti-Angiogenesis and Vascular Targeting in Oncology Results:  First -   Prev -   1 -   2 -   3 -   4 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets3    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network